Vir Biotechnology, Inc. (VIR) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
VIR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VIR Revenue Analysis (2017–2025)
As of March 2, 2026, Vir Biotechnology, Inc. (VIR) generated trailing twelve-month (TTM) revenue of $68.6 million, reflecting explosive growth of +417.8% year-over-year. The most recent quarter (Q4 2025) recorded $64.1 million in revenue, up 26595.8% sequentially.
Looking at the longer-term picture, VIR's 5-year compound annual growth rate (CAGR) stands at +0.4%, indicating moderate growth over time. The company achieved its highest annual revenue of $1.62 billion in 2022.
Revenue diversification analysis shows VIR's business is primarily driven by License And Collaboration Revenue (92%), Other Revenue (5%), and Grant (3%). With over half of revenue concentrated in License And Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY), VIR has outperformed the peer group in terms of revenue growth. Compare VIR vs BNTX →
Peer Comparison
Compare VIR's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VIRCurrent | $69M | +417.8% | +0.4% | -682.7% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $68.6M | -7.6% | $56.9M | 82.9% | $-468,020,000 | -682.7% |
| 2024 | $74.2M | -13.9% | $-404,440,000 | -545.0% | $-587,165,000 | -791.3% |
| 2023 | $86.2M | -94.7% | $-486,647,000 | -564.7% | $-684,305,000 | -794.0% |
| 2022 | $1.62B | +47.5% | $994.8M | 61.6% | $833.1M | 51.6% |
| 2021 | $1.10B | +1529.0% | $581.5M | 53.1% | $420.8M | 38.4% |
| 2020 | $67.2M | +9357.8% | $67.2M | 100.0% | $-296,980,000 | -441.6% |
| 2019 | $711K | -18.1% | $711K | 100.0% | $-177,979,000 | -25032.2% |
| 2018 | $868K | +482.6% | $-99,361,000 | -11447.1% | $-118,692,000 | -13674.2% |
| 2017 | $149K | - | $-62,363,000 | -41854.4% | $-81,497,000 | -54696.0% |
See VIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VIR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VIR vs AGIO
See how VIR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VIR's revenue growth accelerating or slowing?
VIR revenue is accelerating at +417.8% year-over-year, exceeding the 5-year CAGR of +0.4%. TTM revenue reached $69M. Growth momentum has increased versus prior periods.
What is VIR's long-term revenue growth rate?
Vir Biotechnology, Inc.'s 5-year revenue CAGR of +0.4% reflects the sustained expansion pattern. Current YoY growth of +417.8% is above this long-term average.
How is VIR's revenue distributed by segment?
VIR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.